Augustine Therapeutics is proud to be sponsoring and participating to the iPSC Modelling in Neuromuscular Disorders (iMND) conference from October 23-25 in Leuven.

This conference aims to unite scientists from academia as well as industry who use iPSC-derived models to obtain new insights into various motor neuron diseases.

With the support of the US The ALS Association patient advocacy group, Augustine Therapeutic is currently advancing novel and best-in-class, brain penetrant and orally bioavailable selective HDAC6 inhibitors for the potential treatment of motor neuron diseases like Amyotrophic Lateral Sclerosis (ALS)

Find out details of the event and agenda here: Click Here